SANOFI - AMERICAN DEPOSITARY SHARES
SANOFI - AMERICAN DEPOSITARY SHARES
Hinterlegungsschein · US80105N1054 · SNY · 662283 (XNAS)
Übersicht
49,67 USD
-2,28 % -1,16 USD
NASDAQ (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
13.06.2025 20:09

Aktuelle Kurse von SANOFI - AMERICAN DEPOSITARY SHARES

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
SNY
USD
13.06.2025 20:09
49,67 USD
50,83 USD
-2,28 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % -1,11 % -2,34 % -13,99 % 6,13 % 7,39 % -1,82 %

Firmenprofil zu SANOFI - AMERICAN DEPOSITARY SHARES Hinterlegungsschein

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Investierte Fonds

Folgende Fonds haben in investiert: SANOFI - AMERICAN DEPOSITARY SHARES investiert:

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in Mio
395,57
Anteil (%)
0,93 %

Unternehmensdaten

Name SANOFI - AMERICAN DEPOSITARY SHARES
Firma Sanofi
Symbol SNY
Website https://www.sanofi.com
Heimatbörse XNAS NASDAQ
WKN 662283
ISIN US80105N1054
Wertpapierart Hinterlegungsschein
Sektor Healthcare
Branche Drug Manufacturers - General
CEO Mr. Paul Hudson
Marktkapitalisierung 129 Mrd.
Land Frankreich
Währung USD
Mitarbeiter 82,9 T
Adresse 54, Rue La BoEtie, 75008 Paris
IPO Datum 2002-07-01

Aktien-Splits

Datum Split
30.09.2013 5:1
17.11.2010 10:1

Ticker Symbole

Name Symbol
Frankfurt SNW2.F
NASDAQ SNY

Weitere Aktien

Investoren die SANOFI - AMERICAN DEPOSITARY SHARES die halten, haben auch folgende Aktien im Depot:
AMAZON.CO INC
AMAZON.CO INC Aktie
APPLE INC
APPLE INC Aktie
BARCLAYS BK  96/21
BARCLAYS BK 96/21 Anleihe
BAYER AG
BAYER AG Aktie
BRISTOL-MYERS SQUIBB CO
BRISTOL-MYERS SQUIBB CO Aktie
DZ BANK      IS.A2747
DZ BANK IS.A2747 Anleihe
INTERNATIONAL BUSINESS MACHINES CORP
INTERNATIONAL BUSINESS MACHINES CORP Aktie
JPMORGAN CHASE & CO
JPMORGAN CHASE & CO Aktie
KINDER MORGAN INC
KINDER MORGAN INC Aktie
ORACLE CORP
ORACLE CORP Aktie
TAIWAN SEMICON.MANU.ADR/5
TAIWAN SEMICON.MANU.ADR/5 Aktie
TENCENT . LTD
TENCENT . LTD Aktie
UNITEDHEALTH GROUP INC
UNITEDHEALTH GROUP INC Aktie
VISA INC - CLASS A
VISA INC - CLASS A Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025